Advertisement
Advertisement
U.S. markets open in 5 hours 19 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Minerva Neurosciences, Inc. (NERV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.5900+0.0500 (+1.41%)
At close: 04:00PM EST
3.4200 -0.17 (-4.74%)
After hours: 07:40PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close3.5400
Open3.5300
Bid0.0000 x 1100
Ask0.0000 x 900
Day's Range3.5300 - 3.6100
52 Week Range2.5100 - 15.2700
Volume37,755
Avg. Volume507,526
Market Cap19.171M
Beta (5Y Monthly)-0.39
PE Ratio (TTM)N/A
EPS (TTM)-1.1920
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NERV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Minerva Neurosciences, Inc
    Daily Spotlight: Important Inflation News Out TodayThe Federal Reserve's favorite inflation indicator, the PCE Price Index, will be released by the BEA today. The PCE Index differs from the better-known Consumer Price Index in that its components are more variable and are quicker to reflect real-time pricing fluctuations. In the most-recent report (from September), PCE inflation was reported at 6.2% (the latest CPI report, from October, had inflation at 7.7%). At Argus, we forecast a rate of 5.9% for the October PCE Price Index. Core PCE, which removes volatile food and energy prices, was 5.1% in the last month. We expect the Core PCE to tick lower to 5.0% this month. Overall, inflation appears to have peaked during the summer and is starting to decline. We track 21 inflation measures on a monthly basis. On average, they are indicating that prices are rising at a 5.2% rate year-over-year, down from 6.8% last month and from 8.7% four months ago. Drilling down to core inflation (which we obtain by averaging Core CPI, market-based PCE Ex-Food & Energy, the core GDP PCE Price Index, the five-year forward inflation expectation rate, and the 10-year TIPs Break-even Interest Rate), our reading is 4.1%. That's down slightly from our 4.3% reading last month. We note some movement among our components. Producer Prices appear to be cooling off, with substantial declines in PPI Intermediate Prices for Processed and Unprocessed Goods. The rate of wage increases also is slowing. Looking down the road, investors are expecting that the Federal Reserve's series of rate hikes ultimately will tame inflation, with the three-year forward expectation rate now down to 3.1% and the five-year forward expectation rate at 2.3%.
    Rating
    Fair Value
    Economic Moat
    21 hours agoArgus Research
View more
  • GlobeNewswire

    Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

    Company To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended September 30, 2022. Roluperidone Update As announced on August 17, 2022, the company submitted to the U.S. Food and Drug Administration (FDA)

  • GlobeNewswire

    Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

    BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the third quarter of 2022 on Wednesday, November 9, 2022. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates. The live conference call may b

  • Zacks

    Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More

    Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.

Advertisement
Advertisement